Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Index- P/E24.16 EPS (ttm)1.92 Insider Own- Shs Outstand2.65B Perf Week2.72%
Market Cap122.80B Forward P/E14.27 EPS next Y3.25 Insider Trans- Shs Float2.37B Perf Month-3.54%
Income5.12B PEG5.62 EPS next Q- Inst Own9.80% Short Float0.06% Perf Quarter-19.03%
Sales41.72B P/S2.94 EPS this Y-25.50% Inst Trans6.85% Short Ratio0.60 Perf Half Y-14.65%
Book/sh24.34 P/B1.91 EPS next Y1.88% ROA4.20% Target Price52.83 Perf Year-6.70%
Cash/sh2.01 P/C23.04 EPS next 5Y4.30% ROE7.40% 52W Range44.24 - 57.42 Perf YTD-10.36%
Dividend1.91 P/FCF- EPS past 5Y-1.10% ROI6.10% 52W High-19.21% Beta1.04
Dividend %4.12% Quick Ratio1.40 Sales past 5Y2.90% Gross Margin67.50% 52W Low4.86% ATR0.90
Employees112128 Current Ratio1.40 Sales Q/Q4.10% Oper. Margin21.70% RSI (14)44.14 Volatility2.27% 1.40%
OptionableYes Debt/Eq0.29 EPS Q/Q-1.80% Profit Margin12.20% Rel Volume0.66 Prev Close46.81
ShortableYes LT Debt/Eq0.20 EarningsFeb 09 BMO Payout41.90% Avg Volume2.54M Price46.39
Recom2.30 SMA20-0.94% SMA50-3.69% SMA200-10.01% Volume1,682,091 Change-0.90%
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-18-07Upgrade HSBC Securities Neutral → Overweight
Jun-14-07Reiterated Banc of America Sec Buy $50 → $48
Jun-14-07Downgrade JP Morgan Overweight → Neutral
Jun-14-07Downgrade HSBC Securities Overweight → Neutral
Dec-19-14 05:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sanofi of Class Action Lawsuit and Upcoming Deadline -- SNY GlobeNewswire
Dec-18-14 12:08PM  5 Big Stocks to Trade After the Fed's Rate News: Microsoft, Goldman and More at TheStreet
Dec-17-14 07:06PM  Cramer Remix: Here's what the Fed did today at CNBC
06:57PM  Lightning Round: Good stock with a good yield at CNBC
Dec-16-14 04:31PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Sanofi To Contact Brower Piven Before The February 2, 2015 Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Dec-15-14 08:00AM  Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol PR Newswire
Dec-12-14 08:00AM  Sanofi Pasteur Announces FDA Approval of Fluzone® Intradermal Quadrivalent (Influenza Vaccine) for Adults PR Newswire
Dec-11-14 08:10PM  The Big Business of Selling Prescription-Drug Records at BusinessWeek
03:01PM  SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015 -- SNY GlobeNewswire
08:00AM  Livestock products lead Zoetis 3Q14 revenue growth Market Realist
Dec-10-14 06:36PM  Robbins Arroyo LLP: Sanofi (SNY) Misled Shareholders According to a Recently Filed Class Action GlobeNewswire
04:00PM  Must-know trends that drive Zoetis growth Market Realist
08:55AM  Toast The New Year With 5 Undervalued Dividend Stocks at Forbes
08:32AM  Will Sanofi (SNY) Stock Advance Today on Diversification, Acquisitions Strategy? at TheStreet
08:00AM  Pershing Square takes 8.5% stake in Zoetis Market Realist
Dec-09-14 10:10PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sanofi to Contact Brower Piven Before the February 2, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- SNY GlobeNewswire
03:02PM  Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO Benzinga
Dec-08-14 03:30PM  ImmunoGen Reports Encouraging Data on Cancer Drug Zacks
11:48AM  Merck Acquiring Cubist, Focusing On Hospital Care at Investor's Business Daily
09:11AM  Law Offices of Marc S. Henzel Announces Securities Class Action Periods PR Newswire
08:32AM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Sanofi Business Wire
Dec-05-14 10:00PM  SANOFI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sanofi - SNY GlobeNewswire
07:00PM  Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Sanofi -- SNY GlobeNewswire
05:50PM  EQUITY ALERT: Lawsuit Filed Against Sanofi to Recover Investor Losses - SNY GlobeNewswire
04:49PM  Sanofi Buys Merck's Manufacturing Facility in Puerto Rico Zacks
04:37PM  'Kickback' flak: Sanofi's caseload grows bigger at CNBC
Dec-04-14 06:21PM  Pomerantz Law Firm Announces the Filing of a Class Action Against Sanofi and Certain Officers -- SNY GlobeNewswire
04:27PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Sanofi PR Newswire
03:45PM  Sanofi's Priftin Gains U.S. Approval for Latent TB Indication Zacks
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of Sanofi -SNY PR Newswire
Dec-03-14 07:01PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi SNY Business Wire
03:29PM  Sanofi sued over kickbacks CNBC
03:27PM  Lawsuit claims 'kickback' scheme at Sanofi at CNBC
03:14PM  Guess whos opposed to corporate tax reform: Corporations Yahoo Finance
08:00AM  First MS Patients in the U.S. Receive Genzymes Lemtrada Following FDA Approval Business Wire
06:35AM  December 3 Premarket Briefing: 10 Things You Should Know TheStreet
Dec-02-14 12:42PM  Evotec and Sanofi Enter Into Exclusive Negotiations for a Major Multi-Component Strategic Collaboration GlobeNewswire
08:35AM  Sanofi Receives FDA Approval of Priftin® (rifapentine) Tablets for the Treatment of Latent Tuberculosis Infection PR Newswire
Dec-01-14 10:09AM  Australian Diabetes Management Market and Diabetes Diagnostic Devices Market Spurted by $46 Million Between 2005 and 2013 PR Newswire
Nov-28-14 07:02AM  OPEC decision splits ranks CNBC
01:01AM  Pfizer deal probably 'would have fallen apart': AZ CEO at CNBC
Nov-24-14 03:45PM  Sanofi's (SNY) Cerdelga a Step Closer to European Approval Zacks
07:00AM  Sanofi Shakes Off Patent Losses Morningstar
Nov-21-14 04:10PM  Can New Launches Offset Sanofi's Soft Diabetes Business? Zacks
01:55PM  MannKind's Afrezza Remains in Sanofi's Plans, RBC Says at
12:28PM  AbbVie, Celgene, Sanofi Drugs Get EU Endorsements at Investor's Business Daily
10:03AM  Fighting kids' cancer, one voucher at a time at CNBC
07:15AM  European CHMP Adopts Positive Opinion for Genzymes Cerdelga® (eliglustat) Capsules Business Wire
Nov-20-14 03:30PM  Regeneron & Sanofi Present Positive Data on PCSK9 Drug Zacks
03:27PM  Gilead to Buy Knight Therapeutics' Priority Review Voucher Zacks
11:44AM  Sanofi's Bullish Pipeline Forecast Underwhelms Street at Investor's Business Daily
08:50AM  Sanofi's New Medicines day CNBC
08:49AM  New 'Hutch' Director Aims To Push Toward Cancer Cures Based On The Immune System at Forbes
07:54AM  Zacks Industry Outlook Highlights: Mylan, Sanofi, Amgen, Biogen, and Actavis Zacks
01:30AM  Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis PR Newswire
Nov-19-14 02:35PM  Will The IMPROVE-IT Results Impact The Thinking Of The FDA And Payers On LDL-Cholesterol Lowering Drugs? at Forbes
12:24PM  Sanofi's case for experimental drugs in pipeline at CNBC
08:15AM  Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol PR Newswire
08:15AM  Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol PR Newswire
Nov-18-14 03:45PM  Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association Business Wire
03:10PM  Covance (CVD) Sellout Decision to LabCorp: A Strategic Fit? Zacks
11:22AM  Sanofi Names Chief Scientific Officer Gary Nabel as Sanofi Ebola Response Coordinator PR Newswire
Nov-17-14 05:40PM  Alnylam Reports Positive Initial Phase II Data on Revusiran Zacks
04:20PM  Sanofi's Lemtrada Gets U.S. Approval, Carries Boxed Warning Zacks
11:45AM  Surprise! Vytorin Works. Here Are Five Things You Should Know. at Forbes
11:32AM  IMPROVE-IT Meets Endpoint And Demonstrates Real But Modest Clinical Benefit For Ezetimibe at Forbes
08:39AM  After Years Under Attack, Merck's Vytorin Proves Effective at Forbes
Nov-15-14 10:01AM  Amicus Drug Improves Marker of Heart Health in Fabry Patients at TheStreet
Nov-14-14 09:00PM  Genzymes Lemtrada Approved by the FDA Business Wire
03:30PM  Isis/AstraZeneca Expand Antisense Technology Collaboration Zacks
Nov-13-14 10:21AM  A Day Of Reckoning Approaches For Merck And Its Critics at Forbes
Nov-12-14 10:00AM  Regeneron/Sanofi Announce Positive Dupilumab Study Data Zacks
Nov-11-14 12:54PM  Midday movers: Comcast, Macy's, Xerox & more at CNBC
08:20AM  PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y Zacks
01:00AM  Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma PR Newswire
Nov-10-14 08:34AM  The Inaccurate And Unfair WHO Attack On Pharma Ebola Efforts at Forbes
Nov-07-14 08:35AM  What You Need To Know About IMPROVE-IT at Forbes
Nov-06-14 03:45PM  VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up Zacks
Nov-05-14 08:46AM  Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold Zacks
Nov-04-14 08:47PM  This hotel allows you to unlock rooms with your smartphon... CNBC
06:24PM  [$$] 6 Dividend-Paying Stocks From Around the World at
03:30PM  Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance Zacks
01:40PM  Diabetes Analyst: Sanofi CEO's Firing May Spell Trouble for MannKind Afrezza Partnership at TheStreet
12:26PM  [$$] MannKind's Progress Seen More Gradual at
11:40AM  MannKind Falls on Missing Q3 Estimates Yet Cuts Loss Y/Y Zacks
08:49AM  High Drug Prices And Innovation at Forbes
06:00AM  Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis Business Wire
Nov-03-14 08:30AM  Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone® High-Dose Vaccine for Adults 65 and Older PR Newswire
08:03AM  Cleveland Clinic Survey Shows Big Pharma Innovation Renaissance at Forbes
Nov-02-14 09:06PM  Forbes China 400: 10 Richest Pharmaceutical And Healthcare Entrepreneurs at Forbes
Nov-01-14 09:00AM  Saskatchewan to fund treatment with AUBAGIO® for Relapsing Remitting Multiple Sclerosis CNW Group
Oct-31-14 11:20AM  Aegerion Q3 Loss Wider than Expected, 2014 View Lowered Zacks
Oct-30-14 05:25PM  Will Regeneron (REGN) Q3 Earnings be Hit by Higher Costs? Zacks
02:35PM  Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints Zacks
09:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sanofi PR Newswire
06:00AM  Moms, Regulators, Biotech Startups, and the Battle Over a Potentially Life-Saving Drug at BusinessWeek
Oct-29-14 05:58PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs -5.93%
05:45PM  Stock Pops & Drops: NNA, SNY, PNRA &TRN CNBC
12:51PM  Sanofi Axes CEO, Hit By Multiple Downgrades at Investor's Business Daily
12:50PM  Europe closes mixed as Fed eyed; Sanofi tumbles at CNBC
Sanofi discovers, develops, and distributes therapeutic solutions. Its primary products include Lantus and Apidra analogs of human insulin; Insuman insulin solutions and suspensions; Amaryl, a sulfonylurea; Lyxumia, a prandial GLP-1 receptor agonist; BGStar, iBGStar, and MyStar Extra blood glucose meters; Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme for mucopolysaccharidosis Type I; Aubagio for multiple sclerosis; and Lemtrada, a humanized monoclonal antibody. The company's products also comprise Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; Jevtana for prostate cancer; Thymoglobulin, an immuno-suppressive and immuno-modulating agent; Mozobil stem cell mobilizer; and Zaltrap recombinant fusion protein. In addition, it offers thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. Further, it provides Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements for pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has a strategic alliance with Illumina, Inc. to develop a next-generation sequencing based oncology test system. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerOct 16Buy335.35122,12740,955,05722,657,685Oct 20 05:45 PM
Sanofi10% OwnerOct 15Buy328.16158,36851,970,26522,535,558Oct 17 05:05 PM
Sanofi10% OwnerJul 15Buy314.92129,10040,656,17622,204,841Jul 17 05:50 PM
Sanofi10% OwnerJul 14Buy318.18150,00047,726,79722,075,741Jul 15 05:45 PM
Sanofi10% OwnerJul 11Buy315.41150,00047,311,83621,925,741Jul 15 05:45 PM
Sanofi10% OwnerJul 10Buy311.08175,00054,439,07321,775,741Jul 14 05:46 PM
Sanofi10% OwnerJul 09Buy308.27195,00060,112,31121,600,741Jul 10 05:45 PM
Sanofi10% OwnerJul 08Buy311.67153,00047,685,74321,405,741Jul 10 05:45 PM
Sanofi10% OwnerJul 07Buy312.90256,70080,320,79521,252,741Jul 08 05:42 PM
Sanofi10% OwnerJul 03Buy311.02100,00031,101,94620,996,041Jul 08 05:42 PM
Sanofi10% OwnerJul 02Buy307.25212,40065,259,55220,896,041Jul 03 06:00 PM
Sanofi10% OwnerJul 01Buy300.20212,40063,761,42120,683,641Jul 03 05:46 PM
Sanofi10% OwnerJun 30Buy282.54212,40060,010,47920,471,241Jul 01 05:39 PM
Sanofi10% OwnerJun 27Buy275.3850,00013,769,09220,258,841Jul 01 05:39 PM
Sanofi10% OwnerMay 19Buy300.04190,75157,233,71620,208,841May 21 05:02 PM
Sanofi10% OwnerMar 28Buy306.73306,94594,149,58320,018,090Mar 31 06:22 PM
Sanofi10% OwnerMar 27Buy311.01306,94595,463,96319,711,145Mar 31 06:21 PM
Sanofi10% OwnerMar 24Buy307.91306,94594,511,73418,790,310Mar 25 06:11 PM
Sanofi10% OwnerMar 21Buy321.22305,11598,008,22218,483,365Mar 25 06:10 PM
Sanofi10% OwnerMar 20Buy328.4157,95719,033,51118,178,250Mar 21 06:21 PM
Sanofi10% OwnerMar 19Buy327.899,7463,195,65118,120,293Mar 21 06:21 PM
Sanofi10% OwnerMar 17Buy328.5560,12819,755,23418,110,547Mar 18 06:58 PM
Sanofi10% OwnerMar 14Buy328.3655,58318,251,21518,050,419Mar 18 06:58 PM
Sanofi10% OwnerMar 12Buy334.69220,99573,964,41217,994,836Mar 14 05:11 PM
Sanofi10% OwnerMar 11Buy332.26180,71060,043,33617,773,841Mar 12 05:36 PM
Sanofi10% OwnerMar 10Buy328.73199,82265,687,43517,593,131Mar 12 05:36 PM
Sanofi10% OwnerMar 07Buy332.51241,81880,405,73317,393,309Mar 10 09:52 PM
Sanofi10% OwnerMar 07Buy316.2069,87322,093,65517,151,491Mar 10 09:51 PM
Sanofi10% OwnerMar 06Buy339.6080,40427,305,54617,081,618Mar 10 09:51 PM
Sanofi10% OwnerMar 03Buy338.12251,59485,070,11817,001,214Mar 05 08:36 PM
Sanofi10% OwnerFeb 07Buy287.3421,9866,317,45516,749,620Feb 10 06:46 PM
Sanofi10% OwnerFeb 06Buy286.70146,52542,008,39016,727,634Feb 10 06:46 PM
Sanofi10% OwnerFeb 05Buy282.00206,97858,367,10716,581,109Feb 06 07:30 PM
Sanofi10% OwnerFeb 04Buy286.44190,28654,504,78916,374,131Feb 06 07:30 PM
Sanofi10% OwnerFeb 03Buy283.46198,05856,141,71916,183,845Feb 04 07:11 PM
Sanofi10% OwnerJan 31Buy289.6610,9143,161,38315,985,787Feb 04 07:11 PM
Sanofi10% OwnerJan 28Buy278.5483,23523,184,32115,974,873Jan 29 08:20 AM
Sanofi10% OwnerJan 27Buy272.9674,68520,386,04415,891,638Jan 29 08:20 AM